High Antibody-dependent Cellular Cytotoxicity Responses Are Correlated with Strong CD8 T Cell Viral Suppressive Activity but Not with B57 Status in HIV-1 Elite Controllers

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Oct 3

PMID 24086385

Citations 61

Authors

Olivier Lambotte

Justin Pollara

Faroudy Boufassa

Christiane Moog

Alain Venet

Barton F Haynes

Jean-Francois Delfraissy

Asier Saez-Cirion

Guido Ferrari

Affiliations

Soon will be listed here.

Abstract

The role of Antibody-dependent cellular cytotoxicity (ADCC) responses in HIV-1 controllers is still unclear due to the heterogeneity of these patients. We analyzed 67 HIV-1 controllers and found significantly higher levels of ADCC antibodies in controllers versus viremic subjects (p = 0.017). Moreover, multivariate analysis revealed significantly higher ADCC titers in HLA B57- controllers compared to HLA-B57+ ones (p = 0.0086). These data suggest a role for ADCC in immune control of HIV, especially in HLA B57 negative controllers.

Citing Articles

HIV controllers: hope for a functional cure.

Deng Z, Yan H, Lambotte O, Moog C, Su B Front Immunol. 2025; 16:1540932.

PMID: 40070826 PMC: 11893560. DOI: 10.3389/fimmu.2025.1540932.

Innate Immune Cell Functions Contribute to Spontaneous HIV Control.

Huber A, Baas F, van der Ven A, Dos Santos J Curr HIV/AIDS Rep. 2024; 22(1):6.

PMID: 39614998 PMC: 11608392. DOI: 10.1007/s11904-024-00713-0.

Identification of antibody targets associated with lower HIV viral load and viremic control.

Grant-McAuley W, Morgenlander W, Ruczinski I, Kammers K, Laeyendecker O, Hudelson S PLoS One. 2024; 19(9):e0305976.

PMID: 39288118 PMC: 11407625. DOI: 10.1371/journal.pone.0305976.

Comprehensive profiling of pre-infection antibodies identifies HIV targets associated with viremic control and viral load.

Grant-McAuley W, Morgenlander W, Hudelson S, Thakar M, Piwowar-Manning E, Clarke W Front Immunol. 2023; 14:1178520.

PMID: 37744365 PMC: 10512082. DOI: 10.3389/fimmu.2023.1178520.

Comparison of the Biological Basis for Non-HIV Transmission to HIV-Exposed Seronegative Individuals, Disease Non-Progression in HIV Long-Term Non-Progressors and Elite Controllers.

Hokello J, Tyagi P, Dimri S, Sharma A, Tyagi M Viruses. 2023; 15(6).

PMID: 37376660 PMC: 10301403. DOI: 10.3390/v15061362.

References

Peipp M, Lammerts van Bueren J, Schneider-Merck T, Bleeker W, Dechant M, Beyer T . Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood. 2008; 112(6):2390-9. DOI: 10.1182/blood-2008-03-144600. View

Wang J, Balog C, Stavenhagen K, Koeleman C, Scherer H, Selman M . Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics. 2011; 10(5):M110.004655. PMC: 3098587. DOI: 10.1074/mcp.M110.004655. View

Lambotte O, Ferrari G, Moog C, Yates N, Liao H, Parks R . Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS. 2009; 23(8):897-906. PMC: 3652655. DOI: 10.1097/QAD.0b013e328329f97d. View

Potter S, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M . Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol. 2007; 81(24):13904-15. PMC: 2168869. DOI: 10.1128/JVI.01401-07. View

Edmonds T, Ding H, Yuan X, Wei Q, Smith K, Conway J . Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology. 2010; 408(1):1-13. PMC: 2993081. DOI: 10.1016/j.virol.2010.08.028. View

Pollara J, Hart L, Brewer F, Pickeral J, Packard B, Hoxie J . High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A. 2011; 79(8):603-12. PMC: 3692008. DOI: 10.1002/cyto.a.21084. View

Wren L, Chung A, Isitman G, Kelleher A, Parsons M, Amin J . Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology. 2012; 138(2):116-23. PMC: 3575764. DOI: 10.1111/imm.12016. View

Migueles S, Laborico A, Shupert W, Sabbaghian M, Rabin R, Hallahan C . HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol. 2002; 3(11):1061-8. DOI: 10.1038/ni845. View

van Grevenynghe J, Cubas R, Noto A, DaFonseca S, He Z, Peretz Y . Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J Clin Invest. 2011; 121(10):3877-88. PMC: 3195482. DOI: 10.1172/JCI59211. View

10.

Ackerman M, Crispin M, Yu X, Baruah K, Boesch A, Harvey D . Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest. 2013; 123(5):2183-92. PMC: 3637034. DOI: 10.1172/JCI65708. View

11.

Ahmad R, Sindhu S, Toma E, Morisset R, Vincelette J, Menezes J . Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol. 2001; 21(3):227-33. DOI: 10.1023/a:1011087132180. View

12.

Johansson S, Rollman E, Chung A, Center R, Hejdeman B, Stratov I . NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol. 2011; 24(5):359-68. DOI: 10.1089/vim.2011.0025. View

13.

Pereyra F, Addo M, Kaufmann D, Liu Y, Miura T, Rathod A . Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008; 197(4):563-71. DOI: 10.1086/526786. View

14.

McMichael A, Borrow P, Tomaras G, Goonetilleke N, Haynes B . The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol. 2009; 10(1):11-23. PMC: 3119211. DOI: 10.1038/nri2674. View

15.

Haynes B, B Gilbert P, McElrath M, Zolla-Pazner S, Tomaras G, Alam S . Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012; 366(14):1275-86. PMC: 3371689. DOI: 10.1056/NEJMoa1113425. View

16.

French M, Center R, Wilson K, Fleyfel I, Fernandez S, Schorcht A . Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' human leukocyte antigen-B alleles in HIV controllers. AIDS. 2013; 27(4):519-28. DOI: 10.1097/QAD.0b013e32835cb720. View

17.

Hessell A, Hangartner L, Hunter M, Havenith C, Beurskens F, Bakker J . Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007; 449(7158):101-4. DOI: 10.1038/nature06106. View

18.

Forthal D, Landucci G, Haubrich R, Keenan B, Kuppermann B, Tilles J . Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis. 1999; 180(4):1338-41. DOI: 10.1086/314988. View

19.

Saez-Cirion A, Sinet M, Shin S, Urrutia A, Versmisse P, Lacabaratz C . Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol. 2009; 182(12):7828-37. DOI: 10.4049/jimmunol.0803928. View

20.

Alpert M, Harvey J, Lauer W, Reeves R, Piatak Jr M, Carville A . ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog. 2012; 8(8):e1002890. PMC: 3426556. DOI: 10.1371/journal.ppat.1002890. View